222 related articles for article (PubMed ID: 25210203)
1. In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates.
Montagna MT; Lovero G; Coretti C; De Giglio O; Martinelli D; Bedini A; Delia M; Rosato A; Codeluppi M; Caggiano G
J Med Microbiol; 2014 Dec; 63(Pt 12):1638-1643. PubMed ID: 25210203
[TBL] [Abstract][Full Text] [Related]
2. Invitro antifungal susceptibilities of Candida species to liposomal amphotericin B, determined using CLSI broth microdilution, and amphotericin B deoxycholate, measured using the Etest.
Lovero G; Giglio O; Rutigliano S; Diella G; Caggiano G; Montagna MT
J Med Microbiol; 2017 Mar; 66(2):213-216. PubMed ID: 27959780
[TBL] [Abstract][Full Text] [Related]
3. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
4. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
Rudramurthy SM; Jatana M; Singh R; Chakrabarti A
Mycoses; 2013 Jan; 56(1):39-46. PubMed ID: 22519679
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of two amphotericin B formulations against Malassezia furfur strains recovered from patients with bloodstream infections.
Iatta R; Immediato D; Montagna MT; Otranto D; Cafarchia C
Med Mycol; 2015 Apr; 53(3):269-74. PubMed ID: 25631480
[TBL] [Abstract][Full Text] [Related]
6. [In vitro amphotericin B susceptibility of korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and Minimum fungicidal concentration test].
Park JY; Shin JH; Uh Y; Kim EC; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW
Korean J Lab Med; 2008 Oct; 28(5):346-52. PubMed ID: 18971615
[TBL] [Abstract][Full Text] [Related]
7. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
Kovacicova G; Krupova Y; Lovaszova M; Roidova A; Trupl J; Liskova A; Hanzen J; Milosovic P; Lamosova M; Macekova L; Szovenyiova Z; Purgelova A; Obertik T; Bille J; Krcmery V
J Infect Chemother; 2000 Dec; 6(4):216-21. PubMed ID: 11810569
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
Chen SC; Biswas C; Bartley R; Widmer F; Pantarat N; Obando D; Djordjevic JT; Ellis DH; Jolliffe KA; Sorrell TC
Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
[TBL] [Abstract][Full Text] [Related]
11. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.
Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL
J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga M; Alonso R; del Valle O; Rodriguez V; Arévalo MP; Salgado J; Martin-Mazuelos E; Bornay-Llinares FJ; del Palacio A; Cuétara M; Gasser I; Hernández-Molina JM; Pemán J
Chemotherapy; 2000; 46(4):235-44. PubMed ID: 10859429
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
[TBL] [Abstract][Full Text] [Related]
14. Defining Optimal Doses of Liposomal Amphotericin B Against Candida auris: Data From an In Vitro Pharmacokinetic/Pharmacodynamic Model.
Beredaki MI; Sanidopoulos I; Pournaras S; Meletiadis J
J Infect Dis; 2024 Feb; 229(2):599-607. PubMed ID: 38109276
[TBL] [Abstract][Full Text] [Related]
15. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P.
Carrillo-Muñoz AJ; Ruesga M; Brio S; del Valle O; Rodriguez V; Santos P; Hernández-Molina JM; Cantón E; Pemán J; Guarro J; Quindós G
Chemotherapy; 2002 Dec; 48(5):224-31. PubMed ID: 12476038
[TBL] [Abstract][Full Text] [Related]
17. Patterns of amphotericin B killing kinetics against seven Candida species.
Cantón E; Pemán J; Gobernado M; Viudes A; Espinel-Ingroff A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2477-82. PubMed ID: 15215097
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.
Ralph ED; Khazindar AM; Barber KR; Grant CW
Antimicrob Agents Chemother; 1991 Jan; 35(1):188-91. PubMed ID: 2014976
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test.
Ramani R; Chaturvedi V
Antimicrob Agents Chemother; 2000 Oct; 44(10):2752-8. PubMed ID: 10991856
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method.
Pfaller MA; Barry AL
Mycopathologia; 1995; 130(1):3-9. PubMed ID: 7666925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
